The Relevant Clinical trials for the given patient are:

Clinical Trial ID: NCT03901469
Brief Title: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Phase: Phase 2
Inclusion Criteria: inclusion criteria: 

 Females or males age ≥ 18 years (at time of signing informed consent) 

 Parts 1 and 2 only: Histologically confirmed metastatic or recurrent or locally advanced triple-negative breast cancer (estrogen receptor (ER) ≤10%; progesterone receptor (PR) ≤10%; and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) 

 Expansion only: Histologically confirmed metastatic or recurrent, or locally advanced triple-negative breast cancer as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines. 

 Patient is not a candidate for endocrine based therapy, based on Investigator judgement 

 Have a history of progressive disease despite prior therapy 

 Part 1: Have had at least 1 prior cytotoxic chemotherapy. 

 Part 2: Have had no more than 2 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease, unless approved by the Sponsor (no limit on prior targeted anticancer therapies such as mechanistic target or rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF.) 

 Expansion Cohort A (combination treatment in post-TROP2-ADC patients): Have received TROP2-ADC therapy for unresectable locally advanced or metastatic disease. 

 Expansion Cohort B (ZEN003694 monotherapy): Have had at least 1 prior systemic therapy for locally advanced or metastatic disease which may or may not have included a TROP2-ADC. 

 Expansion Cohort C (combination treatment in TROP2-ADC-naive patients): Have had at least 1 prior systemic therapy for locally advanced or metastatic disease and who have not received prior TROP2-ADC therapy. 

 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 

 Part 2 and Expansion only: Measurable disease per RECIST version 1.1 

 
Exclusion Criteria: : 

 Documented germline mutations of BRCA1 or BRCA2 

 Parts 1 and 2 only: Evidence of disease progression during platinum treatment either in the neoadjuvant or in the metastatic setting. For patients receiving platinum in the neoadjuvant setting, at least 6 months must have elapsed between the last dose of platinum-based treatment and enrollment 

 Part 2 only: Patients with inflammatory breast cancer 

 Current or anticipated use of medications known to be strong inhibitors or inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows. Strong inhibitors, inducers or substrates must be discontinued at least 7 days prior to the first administration of study drug. 

 Current or anticipated use within 7 days prior to the first administration of study drug, or during the study, of strong P-gp inhibitors. 

 Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed 

 Prior anticancer therapy (chemotherapy, radiation, hormone therapy, immunotherapy or investigational agent) within 3 weeks from the start of study drug (except for nitrosoureas and mitomycin C within 6 weeks from start of study drug) 

 Parts 1 and 2 only: Radiation to >25% of the bone marrow 

 Treatment with a bone-targeted radionuclide within 6 weeks of first dose of study drug 

 Have previously received an investigational BET inhibitor (including previous participation in studies with the Sponsor's drug, ZEN003694); except for patients in Expansion Cohort B who received ZEN003694 monotherapy and are eligible to cross-over to combination treatment 

 Prior treatment with a PARP inhibitor 

 QTcF interval > 470 msec 

 Insufficient recovery (i.e., has not recovered to at least Grade 1) from prior treatment-related toxicities except for alopecia, fatigue and Grade 2 neuropathy 

 Non-healing wound, ulcer or bone fracture (not including a pathological bone fracture caused by a pre-existing pathological bone lesion) 

 Parts 1 and 2 only: Brain metastases not adequately treated and clinically stable (at the discretion of the Investigator) for at least 3 months prior to the start of study treatment, unless a shorter interval is approved by the Sponsor's Medical Monitor 

 Expansion only: Progressive, symptomatic, or untreated brain metastases. CNS metastases treated definitively with surgery and/or radiation must be radiographically stable based on imaging at least 3 months after definitive treatment. CNS metastases requiring steroid doses equivalent to prednisone doses >10 mg daily or an increase in steroid doses due to CNS disease prior to consent are not eligible 

 Expansion only: Disease initially diagnosed with expression of estrogen receptor (ER) or progesterone receptor (PR) as ≥5% 

 Expansion only: Patients treated with prior endocrine therapy
----------------------------------------------------
The Relevant Clinical trials for the given patient are:

Clinical Trial ID: NCT05252390
Brief Title: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase: Phase 1; Phase 2
Inclusion Criteria: inclusion criteria For All Phases and Cohorts: 

 Recovered from toxicity to prior anti-cancer therapy 

 Adequate bone marrow and organ function 

 Have no known active or symptomatic central nervous system (CNS) disease 

 Cohort-Specific inclusion criteria: In addition to the inclusion criteria listed above, the following criteria apply for enrollment into specific cohorts. 

 Phase 1 (Monotherapy Study; Advanced Solid Tumors) 

 Patients with advanced solid tumors that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available 

 Life expectancy of > 3 months 

 Eastern Cooperative Oncology Group Performance Status ≤ 2 

 Measurable or non-measurable disease 

 Phase 1b (Combination Study with Enzalutamide or Olaparib) 

 Life expectancy of > 3 months 

 Eastern Cooperative Oncology Group Performance Status ≤ 2 

 Measurable or non-measurable disease 

 One of the following tumor types: 

 Ovarian: Platinum-resistant OR platinum- refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting. Patients with BRCA mutation or who are otherwise positive for homologous recombination deficiency must have received prior treatment with a PARP inhibitor. 

 Pancreatic: Progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting. Patients with BRCA mutation must have received prior treatment with a PARP inhibitor. 

 Prostate: mCRPC with progression on or after treatment with at least one androgen receptor-directed therapy. Patients with HRR gene mutation must have received prior treatment with a PARP inhibitor. 

 Breast: Triple-negative breast cancer (TNBC) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting. Patients with BRCA mutation must have received prior treatment with a PARP inhibitor. 

 Other advanced tumors (only Phase 1b dose escalation, NUV-868 + olaparib): the study Medical Monitor must approve enrollment. 

 For all tumor types: Patients will be allowed in the study regardless of their BRCA/HRR status. 

 Phase 2 (Monotherapy Study) and Phase 2b (Combination Study with Enzalutamide or Olaparib) 

 Life expectancy of > 6 months 

 Phase 2b (Select Cohorts Only): At least one measurable lesion defined by standard criteria 

 Eastern Cooperative Oncology Group Performance Status ≤ 1 

 One of the following tumor types: 

 Ovarian: Platinum-resistant or platinum- refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting. Patients with BRCA mutation or who are otherwise positive for homologous recombination deficiency must have received prior treatment with a PARP inhibitor. 

 Pancreatic: Progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting. Patients with BRCA mutation must have received prior treatment with a PARP inhibitor. 

 Prostate: 

 Phase 2 Monotherapy Only: mCRPC with progression on or after treatment with at least one androgen receptor (AR)-directed therapy, and at least one prior treatment with taxane chemotherapy for castration-resistant disease. 

 Phase 2b Combination Only: mCRPC with progression on or after treatment with at least one AR-directed therapy, and no prior taxane chemotherapy for castration-resistant disease. Patients with a deleterious or suspected deleterious germline or somatic HRR gene mutation must have received prior treatment with a PARP inhibitor. 

 Breast: TNBC with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting. Patients with BRCA mutation must have received prior treatment with a PARP inhibitor. 

 For all tumor types: Patients will be allowed in the study regardless of their BRCA/HRR status. 

 
Exclusion Criteria:  For All Phases and Cohorts: 

 Have received chemotherapy, hormonal therapy (except for ongoing luteinizing hormone-releasing hormone [LHRH] analogs in male patients and premenopausal women), radiation, or biological anti-cancer therapy within 14 days prior to the first dose of NUV-868 

 Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days or < 5 half-lives, whichever is longer, for myelosuppressive agent prior to the first dose of study treatment 

 Requires medications that are known to be strong (or moderate for olaparib) inducers and/or strong (or moderate for olaparib) inhibitors of CYP3A4/5 enzymes 

 Female patients who are pregnant of breastfeeding 

 Cohort-Specific 
----------------------------------------------------
The Relevant Clinical trials for the given patient are:

Clinical Trial ID: NCT05382286
Brief Title: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Phase: Phase 3
Inclusion Criteria: Key inclusion criteria: 

 Individuals with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) who have not received previous systemic therapy for advanced disease and whose tumors are programmed cell death ligand 1 (PD-L1) positive at screening. 

 Individuals must have completed treatment for Stage I to III breast cancer, if indicated, and ≥ 6 months must have elapsed between completion of treatment with curative intent and first documented local or distant disease recurrence. 

 Individuals presenting with de novo metastatic TNBC are eligible for this study. 

 TNBC status and tumor PD-L1 combined positive score (CPS) will be confirmed centrally on a recent or archival tumor specimen. 

 Individuals must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria as evaluated locally. 

 Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 

 Demonstrates adequate organ function 

 Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception. 

 Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease. 

 Key 
Exclusion Criteria: : 

 Positive serum pregnancy test or women who are lactating. 

 Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor. 

 Individuals may not have received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment. 

 Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible. 

 Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor. 

 Have an active second malignancy. 

 Have active serious infection requiring antibiotics. 

 Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease. 

 Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 

 Has an active autoimmune disease that has required systemic treatment in the past 2 years. 

 Note: Other protocol defined Inclusion/
----------------------------------------------------
